The hope is that a GLP-1 receptor agonist (or any other anti-obesity medication) could replace medications for a variety of weight-related comorbidities, she said
In the TRIUMPH-1 Phase 3 trial, participants on the 12 mg dose lost an average of 28.3% of their body weight at 80 weeks, and up to 30.3% at 104 weeks in the study extension
For all chronic illnesses, from rheumatoid arthritis to asthma to high blood pressure, patients usually relapse as soon as their treatment stops
For example, if an individual cannot tolerate the lowest dose of semaglutide, they could give themselves a 0.10mg dose that might be better tolerated
doi: 10.1111/cns.13694
PMCID: PMC7942234 ) Cogen AL, Desai K, Elder D, Rosenbach M (2019) Acute photodistributed exanthematous pustulosis associated with liraglutide treatment